If you have been reading about freeze-thaw cycle and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
The precursor to indigo is indican, a colorless, water-soluble derivative of the amino acid tryptophan, and Indigofera leaves contain as much as 0.2–0.8% of this compound. Pressing cut leaves into a vat and soaking hydrolyzes the indican, releasing β-D-glucose and indoxyl. The indoxyl dimerizes in the mixture, and after 12–15 hours of fermentation yields the yellow, water-soluble leucoindigo. Subsequent exposure to air forms the blue, water-insoluble indigo dye. The dye precipitates from the fermented leaf solution upon oxidation, but may also be precipitated when mixed with a strong base such as lye. The solids are filtered, pressed into cakes, dried, and powdered. The powder is then mixed with various other substances to produce different shades of blue and purple. Natural sources of indigo also include mollusks: the Murex genus of sea snails produces a mixture of indigo and 6,6'-dibromoindigo (red), which together produce a range of purple hues known as Tyrian purple. Light exposure during part of the dyeing process can convert the dibromoindigo into indigo, resulting in blue hues known as royal blue, hyacinth purple, or tekhelet.
In April 2023, Monster Beverage Corporation sued independent videogame developer Glowstick Entertainment for their horror party game Dark Deception: Monsters and Mortals. Apparently to Monster Beverage, the use of "Monster" in the title of the game and their green and black logo make it "very confusing" because of the similarities between the two. Glowstick Entertainment's head creator, Vincent Livings, had decided to fight it in court and has since won the case. Additionally later that month, it was discovered that over 100 trademark complaints had been filed in Japan, including complaints against the Pokémon (1996–), Monster Hunter (2004–), and Monster Musume (2012–) franchises, the first of which predates the Monster Energy brand by over half a decade.
Adoniram Judson was the first American missionary to go abroad. On June 17, 1812, the Judsons arrived in Calcutta. When the War of 1812 became known, British officials forced him to leave and he went to Burma in 1813, where he spent four decades as a missionay. Charlotte White (1782-1863) was the first American woman appointed as a missionary and sent to a foreign country. Sponsored by the Baptist Board of Foreign Missions. she embarked for Calcutta, India, in December 1815. Other American missionaries to India during the pre-British Raj era include: Lyman Jewett, Samuel B. Fairbank, Nathan Brown, John Welsh Dulles, Luther Rice, Samuel Newell, David Oliver Allen, Cynthia Farrar, Henry Richard Hoisington, Samuel Nott, Harriet Newell, George Warren Wood, Miron Winslow, Gordon Hall, Azubah Caroline Condit, Levi Spaulding, George Bowen, Ann Hasseltine Judson, George Boardman, Jeremiah Phillips, and William Arthur Stanton.
Sources: en.wikipedia.org
The Gjyshata of Gjirokastra (headquarters: tekke of Asim Bab): the regions of Gjirokastra, Saranda and Tepelena. The Gjyshata of Korça (headquarters: tekke of Turan): the regions of Korça, Devoll, Pogradec and Kolonja, including Leskovik. The Gjyshata of Kruja (headquarters: tekke of Fushë Kruj): the regions of Kruja, Kurbin, Bulqiza, Dibra, Mat, Shkodra and Durrës. The Gjyshata of Elbasan (headquarters: tekke of Baba Xhefai): the regions of Elbasan, Gramsh, Peqin, Lushnja, Kavaja, and Librazhd, including Përrenjas. The Gjyshata of Vlora (headquarters: tekke of Kusum Bab): the regions of Vlora, Mallakastra, Fier, including Patos and Roskovec. The Gjyshata of Berat (headquarters: tekke of Prisht): the regions of Berat, Skrapar and Përmet. During the 1930s, the six gjyshata of Albania set up by Sali Njazi were:
February 20: Decrees enacting the Conventions on the night work of women and of children in industry, drawn up in Washington by the International Labor Conference and signed in Paris on January 24, 1921, by France and Belgium, along with their annexed protocol. August 10: Nationality law. December 6: Decree on the regulations of the École nationale supérieure de céramique in Sèvres, reserved for boys. 1928
=== Approval ratings === In a survey conducted by Ipespe/Febraban and released in February 2023, Lula's third government was rated as good or excellent by 40% of Brazilians, regular by 27%, and bad or terrible by 28%, while 5% did not respond. In the following month, between the 2nd and 6th, Ipec conducted an analysis that was released on the 19th; in it, 41% of Brazilians rated the government as "good or excellent", 30% considered the administration "regular", and 24% thought it was "bad or terrible"; 5% did not know or preferred not to respond. In this way, Lula began his third term with higher approval than his predecessor, Jair Bolsonaro, who in March 2019 was considered "good or excellent" by 34%. Regarding confidence in Lula, 53% of the population said they trusted him, while 43% stated that they did not trust him and 4% preferred not to express an opinion. Finally, the survey found that the president's way of governing had the approval of 57% of Brazilians. On 29 and 30 March, Datafolha interviewed 2,028 people in 126 municipalities, and the Lula government was rated as excellent or good by 38%, regular by 30%, and bad or terrible by 29% of respondents. On 23 May, according to a new survey, 54% of respondents approved of the government, while 39% of respondents disapproved of the government. In June 2023, according to a new Ipec survey, the Lula government had the approval of 37% of the population, while 32% considered it regular, 28% disapproved of it, and 3% did not know how to answer.
=== Synthesis === One synthesis method (shown first) is based on N,N'-dicyclohexylcarbodiimide (DCC) assisted esterification of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine with N-hydroxysuccinimide, followed by a condensation with 2-aminoethyl-2,3-dipalmitoylglycerylphosphoric acid in triethylamine (Et3N). A different approach (shown second) uses N-acetylmuramyl-L-alanyl-D-isoglutamine, hydroxysuccinimide and alanyl-2-aminoethyl-2,3-dipalmitoylglycerylphosphoric acid; that is, the alanine is introduced in the second step instead of the first.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.